Tariffs

Market Access

Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.

News

AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

Market Access

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

News

A deal between the UK and the US will maintain tariffs on imports into the US at 0%, but prices of medicines used by the NHS will go up.

News

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.